- Home
- CNTA vs XENE Comparison
CNTA vs XENE Comparison
Compare CNTA & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | XENE |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CNTA | XENE |
|---|---|---|
| Price | $21.97 | $41.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $37.70 | ★ $53.91 |
| AVG Volume (30 Days) | ★ 1.4M | 873.5K |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,000,000.00 | $7,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 118.88 | N/A |
| 52 Week Low | $9.60 | $26.74 |
| 52 Week High | $30.58 | $46.60 |
Technical Indicators
Market Signals| Indicator | CNTA | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 28.32 | 40.14 |
| Support Level | $22.15 | $40.41 |
| Resistance Level | $23.69 | $42.88 |
| Average True Range (ATR) | 1.03 | 1.69 |
| MACD | -0.36 | -0.48 |
| Stochastic Oscillator | 8.52 | 16.16 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.